Kenji Omae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenji Omae has a total of 265 co-authors. Here are the top co-authors by number of shared publications:
Kazunari Tanabe
Robotic Surgery/Organ Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
54 shared publicationsJunpei Iizuka
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan
44 shared publicationsToshio Takagi
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
42 shared publicationsTsunenori Kondo
Department of Urology, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan
35 shared publicationsHirohito Kobayashi
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan
28 shared publicationsYasunobu Hashimoto
Department of Urology, Tokyo Women's Medical University Aoyama Hospital, Tokyo, Japan
26 shared publications
Latest Publications
- 23 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study
Purpose: To examine cross‐sectional and longitudinal associations between maternal parenting style and nighttime diaper use in early childhood. Methods: We analyzed data from the Japan Environment and Children's Study, a nationwide prospective birth cohort. Maternal parenting styles were categorized as Authoritative, Authoritarian, Permissive, or Uninvolved using responsiveness and demandingness scores from a validated parenting attitude questionnaire. Nighttime diaper use was assessed at ages 3 and 4 years. Multivariable modified Poisson regression with robust error variance was applied to estimate adjusted prevalence ratios (aPRs) for nighttime diaper use at age 3 and adjusted risk ratios (aRRs) for its persistence from ages 3 to 4. Results: The cross‐sectional and longitudinal analyses included 65 765 and 54 915 mother–child pairs, respectively. Compared with the Uninvolved style, aPRs for nighttime diaper use at age 3 were 0.96 (95% CI, 0.95–0.97) for Authoritative, 0.99 (95% CI, 0.98–1.00) for Authoritarian, and 0.99 (95% CI, 0.99–1.00) for Permissive styles. The corresponding aRRs for persistent nighttime diaper use were 0.93 (95% CI, 0.91–0.95), 0.96 (95% CI, 0.94–0.98), and 0.98 (95% CI, 0.96–1.01). No significant interaction was found with child sex, whereas a significant interaction was observed between child developmental status and Authoritarian style. Conclusions: Maternal parenting styles were associated with nighttime diaper use at age 3 and its persistence at age 4. Although nighttime diaper use is not a direct measure of nocturnal continence, these findings suggest that maternal caregiving context may be relevant to early nighttime diaper discontinuation before school age. Trial Registration: ClinicalTrials.gov identifier: UMIN000030786
- 23 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study
Purpose: To examine cross‐sectional and longitudinal associations between maternal parenting style and nighttime diaper use in early childhood. Methods: We analyzed data from the Japan Environment and Children's Study, a nationwide prospective birth cohort. Maternal parenting styles were categorized as Authoritative, Authoritarian, Permissive, or Uninvolved using responsiveness and demandingness scores from a validated parenting attitude questionnaire. Nighttime diaper use was assessed at ages 3 and 4 years. Multivariable modified Poisson regression with robust error variance was applied to estimate adjusted prevalence ratios (aPRs) for nighttime diaper use at age 3 and adjusted risk ratios (aRRs) for its persistence from ages 3 to 4. Results: The cross‐sectional and longitudinal analyses included 65 765 and 54 915 mother–child pairs, respectively. Compared with the Uninvolved style, aPRs for nighttime diaper use at age 3 were 0.96 (95% CI, 0.95–0.97) for Authoritative, 0.99 (95% CI, 0.98–1.00) for Authoritarian, and 0.99 (95% CI, 0.99–1.00) for Permissive styles. The corresponding aRRs for persistent nighttime diaper use were 0.93 (95% CI, 0.91–0.95), 0.96 (95% CI, 0.94–0.98), and 0.98 (95% CI, 0.96–1.01). No significant interaction was found with child sex, whereas a significant interaction was observed between child developmental status and Authoritarian style. Conclusions: Maternal parenting styles were associated with nighttime diaper use at age 3 and its persistence at age 4. Although nighttime diaper use is not a direct measure of nocturnal continence, these findings suggest that maternal caregiving context may be relevant to early nighttime diaper discontinuation before school age. Trial Registration: ClinicalTrials.gov identifier: UMIN000030786
- 24 June 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (4)
The Fukushima Daiichi Nuclear Power Plant accident did not increase the incidence of cryptorchidism: an interrupted time series analysis
Background: It has been hypothesized that the incidence of cryptorchidism may have increased in Japan following the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident in March 2011; however, empirical evidence remains limited. This study aimed to assess the possible impact of the accident on cryptorchidism incidence over an extended period of time before and after the accident. Methods: Detailed information on all patients who underwent orchiopexy between April 2008 and March 2021 was obtained from the medical records of 86 hospitals in Fukushima Prefecture. Interrupted time series analyses were performed to evaluate the immediate post- versus pre-accident level change and the monthly post- versus pre-accident slope change in orchiopexy surgery rates and birth rates with cryptorchidism. Results: In total, 622 orchiopexy surgeries performed in Fukushima Prefecture during the study period were included. No significant increase was observed in the monthly orchiopexy surgery rate per 100 000 population in Fukushima Prefecture after the accident, in terms of either the immediate level change (incidence rate ratio [IRR], 1.21; 95% CI, 0.86–1.70) or the monthly slope change (IRR per month, 1.01; 95% CI, 0.99–1.04). The estimated monthly birth rate with cryptorchidism per 1000 live births in Fukushima Prefecture also showed no significant increase in either the immediate level change (IRR, 0.87; 95% CI, 0.52–1.44) or the monthly slope change (IRR per month, 1.01; 95% CI, 0.99–1.04). Conclusions: Our study provided no evidence that the FDNPP accident increased the orchiopexy surgery rates or birth rates with cryptorchidism in Fukushima Prefecture.
- 24 June 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (4)
The Fukushima Daiichi Nuclear Power Plant accident did not increase the incidence of cryptorchidism: an interrupted time series analysis
Background: It has been hypothesized that the incidence of cryptorchidism may have increased in Japan following the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident in March 2011; however, empirical evidence remains limited. This study aimed to assess the possible impact of the accident on cryptorchidism incidence over an extended period of time before and after the accident. Methods: Detailed information on all patients who underwent orchiopexy between April 2008 and March 2021 was obtained from the medical records of 86 hospitals in Fukushima Prefecture. Interrupted time series analyses were performed to evaluate the immediate post- versus pre-accident level change and the monthly post- versus pre-accident slope change in orchiopexy surgery rates and birth rates with cryptorchidism. Results: In total, 622 orchiopexy surgeries performed in Fukushima Prefecture during the study period were included. No significant increase was observed in the monthly orchiopexy surgery rate per 100 000 population in Fukushima Prefecture after the accident, in terms of either the immediate level change (incidence rate ratio [IRR], 1.21; 95% CI, 0.86–1.70) or the monthly slope change (IRR per month, 1.01; 95% CI, 0.99–1.04). The estimated monthly birth rate with cryptorchidism per 1000 live births in Fukushima Prefecture also showed no significant increase in either the immediate level change (IRR, 0.87; 95% CI, 0.52–1.44) or the monthly slope change (IRR per month, 1.01; 95% CI, 0.99–1.04). Conclusions: Our study provided no evidence that the FDNPP accident increased the orchiopexy surgery rates or birth rates with cryptorchidism in Fukushima Prefecture.
- Open Access
- 20 May 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 80 (9) , 740-747
Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study
Aim: To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods: We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated risks and high cost. We calculated SWD as the minimum required increase in the possibility of maintaining cognitive function (relative to the 50% without lecanemab) that patients would accept in exchange for the burdens of treatment (adverse effects, costs, other inconveniences). We examined the median SWD for two scenarios: a family member (SWD‐families) and others (SWD‐others), and analyzed subgroup differences. Results: The median SWD revealed a 15% increase for SWD‐families and SWD‐others. This value exceeds the drug's actual efficacy of an 8% increase. Notably, 17% of respondents reported zero SWD, driven by an intense fear of AD and possibly high expectations from media coverage. Including these participants, nearly half of the respondents considered the current effect worthwhile. No noticeable difference was found between the SWD‐families and SWD‐others. Conclusion: Based on Japanese clinical scenarios, the public's median expectation for lecanemab exceeds its efficacy, though its current benefit remains acceptable to nearly half the population. These findings underscore that the SWD is shaped by psychological drivers, including fear and hope, rather than just reasoned evaluation. Clinicians must manage these expectations, accounting for highly heterogeneous treatment preferences. Future research should account for emotional factors that can overshadow a rational assessment of treatment value.
- 20 May 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 80 (9) , 740-747
Open AccessPublic acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study
Aim: To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods: We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated risks and high cost. We calculated SWD as the minimum required increase in the possibility of maintaining cognitive function (relative to the 50% without lecanemab) that patients would accept in exchange for the burdens of treatment (adverse effects, costs, other inconveniences). We examined the median SWD for two scenarios: a family member (SWD‐families) and others (SWD‐others), and analyzed subgroup differences. Results: The median SWD revealed a 15% increase for SWD‐families and SWD‐others. This value exceeds the drug's actual efficacy of an 8% increase. Notably, 17% of respondents reported zero SWD, driven by an intense fear of AD and possibly high expectations from media coverage. Including these participants, nearly half of the respondents considered the current effect worthwhile. No noticeable difference was found between the SWD‐families and SWD‐others. Conclusion: Based on Japanese clinical scenarios, the public's median expectation for lecanemab exceeds its efficacy, though its current benefit remains acceptable to nearly half the population. These findings underscore that the SWD is shaped by psychological drivers, including fear and hope, rather than just reasoned evaluation. Clinicians must manage these expectations, accounting for highly heterogeneous treatment preferences. Future research should account for emotional factors that can overshadow a rational assessment of treatment value.
- Open Access
- 21 April 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (4) , e70468
Prescribing Patterns and Treatment Persistence for Overactive Bladder in Japan Across Medical Specialties and Facility Types: A Nationwide Claims Database Study
Objectives: To describe real‐world initial pharmacotherapy, treatment persistence, and diagnostic testing for overactive bladder in Japan by medical specialty and facility type. Methods: This retrospective descriptive study used nationwide administrative claims data. Patients aged 15 years or older diagnosed with overactive bladder in 2022 who newly initiated pharmacotherapy were followed for 1 year. Analyses were conducted across four groups defined by medical specialty and facility type. We summarized initial medication, baseline comorbidities, one‐year treatment persistence, and performance of urinalysis and postvoid residual volume measurement at diagnosis and within 1–3 months thereafter. Results: Of 702 078 patients diagnosed with overactive bladder, 65 173 met the eligibility criteria (median age 80 years; interquartile range 74.0–85.0; women 56.3%). β3‐adrenoceptor agonists accounted for more than 70% of initial prescriptions in both urology and internal medicine, whereas anticholinergics were used more often in internal medicine than in urology. Baseline comorbidities, including dementia, were broadly similar between patients initiating β3‐adrenoceptor agonists and those initiating anticholinergics, except for benign prostatic hyperplasia. At 1 year, persistence was higher for β3‐adrenoceptor agonists than for anticholinergics and other drugs, but remained below 30% for β3‐adrenoceptor agonists. Urinalysis and postvoid residual volume measurement were performed more frequently in urology than in internal medicine. Conclusions: β3‐adrenoceptor agonists predominated as initial pharmacotherapy for overactive bladder in Japan, whereas anticholinergics were used more often in internal medicine than in urology. Similar comorbidity profiles and specialty‐related differences in diagnostic testing highlight opportunities to optimize individualized prescribing and strengthen guideline‐concordant evaluation across care settings.
- 21 April 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (4) , e70468
Open AccessPrescribing Patterns and Treatment Persistence for Overactive Bladder in Japan Across Medical Specialties and Facility Types: A Nationwide Claims Database Study
Objectives: To describe real‐world initial pharmacotherapy, treatment persistence, and diagnostic testing for overactive bladder in Japan by medical specialty and facility type. Methods: This retrospective descriptive study used nationwide administrative claims data. Patients aged 15 years or older diagnosed with overactive bladder in 2022 who newly initiated pharmacotherapy were followed for 1 year. Analyses were conducted across four groups defined by medical specialty and facility type. We summarized initial medication, baseline comorbidities, one‐year treatment persistence, and performance of urinalysis and postvoid residual volume measurement at diagnosis and within 1–3 months thereafter. Results: Of 702 078 patients diagnosed with overactive bladder, 65 173 met the eligibility criteria (median age 80 years; interquartile range 74.0–85.0; women 56.3%). β3‐adrenoceptor agonists accounted for more than 70% of initial prescriptions in both urology and internal medicine, whereas anticholinergics were used more often in internal medicine than in urology. Baseline comorbidities, including dementia, were broadly similar between patients initiating β3‐adrenoceptor agonists and those initiating anticholinergics, except for benign prostatic hyperplasia. At 1 year, persistence was higher for β3‐adrenoceptor agonists than for anticholinergics and other drugs, but remained below 30% for β3‐adrenoceptor agonists. Urinalysis and postvoid residual volume measurement were performed more frequently in urology than in internal medicine. Conclusions: β3‐adrenoceptor agonists predominated as initial pharmacotherapy for overactive bladder in Japan, whereas anticholinergics were used more often in internal medicine than in urology. Similar comorbidity profiles and specialty‐related differences in diagnostic testing highlight opportunities to optimize individualized prescribing and strengthen guideline‐concordant evaluation across care settings.
- 21 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102565
CT-Measured Psoas Area Predicts Urinary Incontinence Trajectories and Persistence After Robotic Prostatectomy: A 12-Month Analysis Using the 1-Hour Pad Test
- 21 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102565
CT-Measured Psoas Area Predicts Urinary Incontinence Trajectories and Persistence After Robotic Prostatectomy: A 12-Month Analysis Using the 1-Hour Pad Test
- Open Access
Estimating the Smallest Worthwhile Difference (SWD) of Psychotherapy for Alcohol Use Disorder: Protocol for a Cross-Sectional Survey
Background: Psychotherapy is proven efficacious for the treatment of alcohol use disorder (AUD). However, the patient-perceived importance of its effect is not fully appreciated in the evidence base. The smallest worthwhile difference (SWD) represents the smallest beneficial effect of an intervention that patients deem worthwhile in exchange for the harms, expenses, and inconveniences associated with the intervention, and facilitates the interpretation of patient perceived worthiness of an intervention. Methods: The proposed study will estimate the SWD of NIAAA recommended psychotherapies for AUD treatment with English-speaking American respondents aged 18 and older. Primary participants will be recruited using the Prolific research crowdsourcing site. The SWD will be estimated using the Benefit-Harm Trade-off Method, presenting survey respondents with variable, hypothetical magnitudes of psychotherapy outcomes to find the smallest acceptable effect over a natural recovery alternative. The overall average SWD, and subgroup distributions by participant AUD treatment experiences and AUD symptomology will be described. Secondary findings will estimate the smallest recommendable risk difference for AUD psychotherapy from providers and criminal justice professionals. Expected Results: We expect to find an estimate of the SWD for AUD psychotherapy. Further, we expect that the SWD will vary between clinical subgroups based on AUD symptomology and treatment experiences. We expect differences in SWDs between the general population and those of providers and criminal justice professionals. Findings from this project will inform the treatment decision process about psychotherapy during the clinical consultation for people with AUD.
Open AccessEstimating the Smallest Worthwhile Difference (SWD) of Psychotherapy for Alcohol Use Disorder: Protocol for a Cross-Sectional Survey
Background: Psychotherapy is proven efficacious for the treatment of alcohol use disorder (AUD). However, the patient-perceived importance of its effect is not fully appreciated in the evidence base. The smallest worthwhile difference (SWD) represents the smallest beneficial effect of an intervention that patients deem worthwhile in exchange for the harms, expenses, and inconveniences associated with the intervention, and facilitates the interpretation of patient perceived worthiness of an intervention. Methods: The proposed study will estimate the SWD of NIAAA recommended psychotherapies for AUD treatment with English-speaking American respondents aged 18 and older. Primary participants will be recruited using the Prolific research crowdsourcing site. The SWD will be estimated using the Benefit-Harm Trade-off Method, presenting survey respondents with variable, hypothetical magnitudes of psychotherapy outcomes to find the smallest acceptable effect over a natural recovery alternative. The overall average SWD, and subgroup distributions by participant AUD treatment experiences and AUD symptomology will be described. Secondary findings will estimate the smallest recommendable risk difference for AUD psychotherapy from providers and criminal justice professionals. Expected Results: We expect to find an estimate of the SWD for AUD psychotherapy. Further, we expect that the SWD will vary between clinical subgroups based on AUD symptomology and treatment experiences. We expect differences in SWDs between the general population and those of providers and criminal justice professionals. Findings from this project will inform the treatment decision process about psychotherapy during the clinical consultation for people with AUD.
- 16 February 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 175
Determining the smallest worthwhile difference of beta-3 agonist treatment for overactive bladder: a benefit-harm trade-off study
- 16 February 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 175
Determining the smallest worthwhile difference of beta-3 agonist treatment for overactive bladder: a benefit-harm trade-off study
- 10 November 2025
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-8
Estimating the smallest worthwhile difference of recommended psychotherapies for depression: observational study
Background: The smallest worthwhile difference (SWD) represents the smallest beneficial effect of an intervention that patients deem worthwhile given the harms, expenses and inconveniences of the intervention. The SWD facilitates interpretation of the patient-perceived importance of intervention effects. We previously estimated the SWD for antidepressants for depression, but the SWD for psychotherapy remains unknown. Aims: To estimate the SWD of recommended psychotherapies for depression compared with no treatment. Method: We estimated the SWD through a patient required difference in response rates between psychotherapy and no treatment after 2 months. We recruited using Prolific, an online cross-sectional survey platform, in the UK and USA in January 2025. We also queried a random subset of respondents to replicate our previous SWD estimation for antidepressants. Results: In the primary study, we recruited 526 participants (mean age: 36.7 years (s.d. = 12.5); 54% women and 61% White individuals). Of these, 6% reported that they would not initiate psychotherapy with a 100% treatment response. For those willing to initiate psychotherapy, 87 reported moderate-to-severe depressive symptoms but were not in treatment, 184 were in treatment and 131 reported absent-to-mild symptoms with or without previous treatment. The median SWD for people with moderate-to-severe depressive symptoms, not in treatment and willing to consider psychotherapies was a 20% (interquartile range: 10–35%) difference in response rates comparing psychotherapy with no treatment. This was similar to the SWD for antidepressant drugs (SWD = 20%, interquartile range: 10–30%; n = 104). Participant characteristics were not meaningfully associated with the SWD. Conclusions: Current empirically supported psychotherapy response rates of 15% were sufficient for one in three people to initiate psychotherapy given the burdens, but two in three expected greater treatment benefits or fewer burdens. The SWD for psychotherapy was not materially different from the estimated SWD for antidepressants. Individual patient value judgements and preferences merit greater attention. These findings should be replicated with diverse samples from different geographical locations.
- 10 November 2025
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-8
Estimating the smallest worthwhile difference of recommended psychotherapies for depression: observational study
Background: The smallest worthwhile difference (SWD) represents the smallest beneficial effect of an intervention that patients deem worthwhile given the harms, expenses and inconveniences of the intervention. The SWD facilitates interpretation of the patient-perceived importance of intervention effects. We previously estimated the SWD for antidepressants for depression, but the SWD for psychotherapy remains unknown. Aims: To estimate the SWD of recommended psychotherapies for depression compared with no treatment. Method: We estimated the SWD through a patient required difference in response rates between psychotherapy and no treatment after 2 months. We recruited using Prolific, an online cross-sectional survey platform, in the UK and USA in January 2025. We also queried a random subset of respondents to replicate our previous SWD estimation for antidepressants. Results: In the primary study, we recruited 526 participants (mean age: 36.7 years (s.d. = 12.5); 54% women and 61% White individuals). Of these, 6% reported that they would not initiate psychotherapy with a 100% treatment response. For those willing to initiate psychotherapy, 87 reported moderate-to-severe depressive symptoms but were not in treatment, 184 were in treatment and 131 reported absent-to-mild symptoms with or without previous treatment. The median SWD for people with moderate-to-severe depressive symptoms, not in treatment and willing to consider psychotherapies was a 20% (interquartile range: 10–35%) difference in response rates comparing psychotherapy with no treatment. This was similar to the SWD for antidepressant drugs (SWD = 20%, interquartile range: 10–30%; n = 104). Participant characteristics were not meaningfully associated with the SWD. Conclusions: Current empirically supported psychotherapy response rates of 15% were sufficient for one in three people to initiate psychotherapy given the burdens, but two in three expected greater treatment benefits or fewer burdens. The SWD for psychotherapy was not materially different from the estimated SWD for antidepressants. Individual patient value judgements and preferences merit greater attention. These findings should be replicated with diverse samples from different geographical locations.